New Delhi, Feb. 25 -- Biocon share price rose by 2.5% during Tuesday's trading session following the launch of a biosimilar product by its subsidiary, Biocon Biologics, aimed at treating specific autoimmune disorders in the US market. The product, Yesintek (ustekinumab-kfce), has received approval for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, and is now accessible to patients in the US, according to a statement from the company. This biosimilar product is designed to be comparable to Stelara.

Shreehas Tambe, CEO & Managing Director of Biocon Biologics Ltd, stated that the introduction of Yesintek represents an important advancement in our dedication to enhancing the well-being of pat...